Chromium is a trace mineral thought to help insulin clear sugar from the blood. The clearest benefit is modest better blood-sugar control in people who already have type 2 diabetes or clear insulin resistance. Weight and cholesterol effects are minimal. Safety at typical doses is generally good, but it is far weaker than diet, exercise, and sleep. (Full Review)

Protocol

Dose

200–1,000 µg/day

Elemental chromium; metabolic effects more associated with ≥500–1,000 µg/day

Preferred Form

Chromium picolinate

Organic, better-absorbed forms (picolinate, nicotinate, yeast) over chromium chloride

Timing

With a meal

Carbohydrate-containing meal; single or split (e.g., 200 µg twice daily) dosing

Time to effect

Glycemic Markers

8–16 weeks

Benefit develops gradually over weeks; fair trial needs at least 2–3 months with before-and-after markers

Weight Change

8–24 weeks

Average placebo-subtracted loss is small (~0.5–1.1 kg)

Benefits

Medium: Improved glycemic control in type 2 diabetes

Low: Modest weight and body-composition effects; reduced insulin resistance in PCOS; reduction in high-dose triglycerides

Speculative: Reduced sugar/carbohydrate cravings; longevity or healthy-aging effects

Contraindications

Chronic kidney disease (eGFR <60; avoid in stage 4–5)

Significant liver disease

Pregnancy and breastfeeding (not above adequate-intake levels)

Chromium hypersensitivity

Diabetes on medication (not without clinician oversight)

Key Interactions

Antidiabetic medications (insulin, metformin, sulfonylureas, meglitinides)

Levothyroxine (separate by 3–4 hours)

NSAIDs and aspirin (ibuprofen, aspirin, naproxen)

Antacids, H2 blockers, proton pump inhibitors

Glucose-lowering supplements (berberine, alpha-lipoic acid, cinnamon, bitter melon, gymnema, magnesium)

Mineral competition (iron, zinc, calcium)

Vitamin C (enhances absorption)

Risk & Side Effects

Low: Mild gastrointestinal and neurological symptoms; hypoglycemia when combined with glucose-lowering therapy

Speculative: Renal and hepatic injury at very high doses; theoretical DNA oxidative damage from picolinate; hexavalent chromium contamination

Monitoring

Marker	Target	Why
Fasting glucose	70–85 mg/dL	Tracks chromium's main proposed effect on blood sugar
Hemoglobin A1c (HbA1c)	<5.4%	Reflects average glucose over ~3 months; primary efficacy endpoint
Fasting insulin	2–6 µIU/mL	Detects insulin resistance, the state most likely to respond
HOMA-IR	<1.5	Composite index of insulin resistance and likely responder status
Triglycerides	<90 mg/dL	High-dose chromium may modestly lower triglycerides
eGFR / creatinine	eGFR >90 mL/min/1.73m²	Safety check given rare high-dose kidney injury reports

Cadence: Baseline, then recheck glycemic markers at ~12 weeks and every 3–6 months if continued; more frequent blood-glucose checks (1–4 weeks) for anyone on glucose-lowering medication.

Qualitative Assessment

Sugar and carbohydrate cravings
Energy and post-meal stability
Appetite and weight trend
Tolerability (absence of headache, GI upset, or hypoglycemic symptoms)

Chromium for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment